We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Topical Nanotechnology Simplifies Skin Disease Diagnosis

By LabMedica International staff writers
Posted on 30 May 2018
Print article
Image: A diagram of simplifying disease diagnosis using topically applied nanotechnology could change the way skin diseases such as abnormal scars are diagnosed and managed (Photo courtesy of Nanyang Technological University).
Image: A diagram of simplifying disease diagnosis using topically applied nanotechnology could change the way skin diseases such as abnormal scars are diagnosed and managed (Photo courtesy of Nanyang Technological University).
Tissue biopsies are necessary for the accurate diagnosis of skin diseases, but their application is limited by the pain, inconvenience, and morbidity experienced by patients, as well as risks of scarring and infection.

Many skin diseases, such as abnormal scars, are typically identified by visual identification of scar lesions; however, a visible scar is already mature, having generated significant newly formed tissue, and is unable to benefit from timely administration of prophylactics.

Scientists at the Nanyang Technological University (Singapore) used NanoFlare to enable biopsy-free disease diagnosis and progression monitoring in response to therapy. It is a minimally-invasive, self-applied alternative that can reduce scarring and infection risks; improve accessibility to disease diagnosis; provide timely feedback of treatment efficacy; and reduce healthcare personnel time and attention, hence the overall healthcare burden.

NanoFlares are inactive and emission signal remains low. NanoFlares targeting reference genes (i.e., Glyceraldehyde-3-Phosphate Dehydrogenase (GapDH) and noncoding sequences) can be simultaneously employed for signal normalization. Thus, abnormal fibroblasts can be discriminated from non-diseased ones by their fluorescence signal. In this process, NanoFlares maintain their detection properties and molecular specificity following transepidermal and intracellular entry.

Transdermal NanoFlare penetration is the results from their unique nanostructure. They comprise highly packed oligonucleotide strands directionally aligned to cores (comprising a range of different materials, including gold) and even hollow-core nanoparticles. This gives the resultant particles a strong negative surface charge.

NanoFlares are topically applied on the lesion, which penetrate the skin barrier, interacting with intracellular mRNA biomarkers. In the presence of the target gene (e.g., disease biomarker or other control genes), mRNA interacts with the NanoFlare, dislodging (releasing) the reporter flare. Leaving the proximity of the gold nanoparticle core, a strong fluorescence is generated. Without target gene hybridization, fluorescence signal does not appreciably increase but remains below background levels. In the presence of sufficient disease biomarker, fluorescence signal can be superficially acquired.

The authors concluded that NanoFlare technology is a minimally-invasive, self-applied alternative that can reduce scarring and infection risks; improve accessibility to disease diagnosis; provide timely feedback of treatment efficacy; and reduce healthcare personnel time and attention, hence the overall healthcare burden. This vision of simplifying disease diagnosis using topically applied nanotechnology could change the way skin diseases such as abnormal scars are diagnosed and managed. The study was published on April 13, 2018, in the journal Nature Biomedical Engineering.

Related Links:
Nanyang Technological University

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
PSA Test
Humasis PSA Card
New
Creatine Kinase-MB Assay
CK-MB Test

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: Karius Focus BAL is designed to quickly identify the etiology of lung infections and improve diagnostic yield over standard of care testing (Photo courtesy of Karius)

Microbial Cell-Free DNA Test Accurately Identifies Pathogens Causing Pneumonia and Other Lung Infections

Bronchoalveolar lavage (BAL) is a commonly used procedure for diagnosing lung infections, especially in immunocompromised patients. However, standard tests often fail to pinpoint the exact pathogen, leading... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.